Mirabegron for the treatment of overactive bladder

Drugs of Today

Volumn 48, Issue 1, 2012, Pages 25-32

  Gras, Jordi ^a  

^a C/Roger de Flor 3   (Spain)

Author keywords

Mirabegron; Overactive bladder; YM 178

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APREPITANT; BETA ADRENERGIC RECEPTOR; BETANIS; BOTULINUM TOXIN A; COLECALCIFEROL DERIVATIVE; CYCLIC AMP; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DARIFENACIN; DESIPRAMINE; FESOTERODINE; GLUCOSE; KETOCONAZOLE; METFORMIN; MIRABEGRON; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROPIVERINE; RIFAMPICIN; SOLIFENACIN; TOLTERODINE; TRAMADOL; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BLADDER; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICATION THERAPY MANAGEMENT; MIXED INCONTINENCE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVERACTIVE BLADDER; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTVOID RESIDUAL URINE VOLUME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SENSORY NERVE; SINGLE DRUG DOSE; SINUSITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

EID: 84857672160     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.1.1738056     Document Type: Review

References (45)

1. Haylen, B.T., de Ridder, D., Freeman, R.M. et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010, 21(1): 5-26.
2. Abrams, P. Describing bladder storage function: Overactive bladder syndrome and detrusor overactivity. Urology 2003, 62(5, Suppl. 2): 28-37. (Pubitemid 37510015)
3. Aschkenazi, S., Botros, S., Miller, J., Gamble, T., Sand, P., Goldberg, R. Overactive bladder symptoms are not related to detrusor overactivity. Neurourol Urodyn [37th Annu Meet Int Continence Soc (Aug 20-24, Rotterdam) 2007] 2007, 26(5): Abst 35.
4. Andersson, K.E. Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol 2009, 1(2): 71-83.
5. Irwin, D.E., Milsom, I., Hunskaar, S. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006, 50(6): 1306-14.
6. Currie, C.J., McEwan, P., Poole, C.D. et al. The impact of the overactive bladder on health-related utility and quality of life. BJU Int 2006, 97(6): 1267-72. (Pubitemid 43907335)
7. Stewart, W.F., Van Rooyen, J.B., Cundiff, G.W. et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20(6): 327-36. (Pubitemid 44175300)
8. Homma, Y., Yamaguchi, O., Hayashi, K. et al. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 2005, 96(9): 1314-8. (Pubitemid 41743931)
9. Coyne, K.S., Sexton, C.C., Irwin, D.E., Kopp, Z.S., Kelleher, C.J., Milsom, I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: Results from the EPIC study. BJU Int 2008, 101(11): 1388-95. (Pubitemid 351623990)
10. Reeves, P., Irwin, D., Kelleher, C., Milsom, I., Kopp, Z., Calvert, N., Lloyd, A. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006, 50(5): 1050-7. (Pubitemid 44486484)
11. Gutur, D.M., Drake, M.J. Management of overactive bladder. Nat Rev Urol 2010, 7(10): 572-82.
12. Novara, G., Galfano, A., Secco, S., D'Elia, C., Cavalleri, S., Ficarra, V., Artibani, W. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008, 54(4): 740-63.
13. Benner, J.S., Nichol, M.B., Rovner, E.S. et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010, 105(9): 1276-82.
14. Andersson, K.E. Drugs and future candidates. Can Urol Assoc J 2011, 5(5, Suppl. 2): S131-3.
15. Colli, E., Digesu, G.A., Olivieri, L. Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 2007, 16(7): 999-1007. (Pubitemid 47078776)
16. Stief, C.G., Porst, H., Neuser, D., Beneke, M., Ulbrich, E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008, 53(6): 1236-44.
17. Sahai, A., Dowson, C., Khan, M. S., Dasgupta, P. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: Results from a randomized double-blind placebo-controlled trial. BJU Int 2009, 103(11): 1509-15.
18. Rovner, E.S., Kreder, K., Sussman, D.O., Kaplan, S.A., Carlsson, M., Bavendam, T., Guan, Z. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008, 180(3): 1034-41.
19. Safarinejad, M.R., Hosseini, S.Y. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: A double-blind, placebo controlled, randomized study. Br J Clin Pharmacol 2006, 61(4): 456-63.
20. Green, S.A., Alon, A., Ianus, J., McNaughton, K.S., Tozzi, C.A., Reiss, T.F. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006, 176(6): 2535-40. (Pubitemid 44665982)
21. Andersson, K.E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993, 45(3): 253-308.
22. Michel, M.C., Vrydag, W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006, 147(Suppl. 2): S88-119.
23. Takeda, H., Yamazaki, Y., Igawa, Y. et al. Effects of beta(3)- adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn 2002, 21(6): 558-65. (Pubitemid 35204816)
24. Approval for Betanis® tablet, a treatment for OAB, in Japan [news release]. Astellas Pharma Inc., July 1, 2011. http://www.astellas.com/en/ corporate/news/detail/approval-for-betanis-tablet-a.html. Accessed January 26, 2012.
25. Announcement of regulatory submission for mirabegron (YM718), a treatment for overactive bladder, in U.S. and Europe [news release]. Astellas Pharma Inc., August 29, 2011. http://www.astellas.com/en/corporate/news/pdf/110829-Eg. pdf. Accessed January 26, 2012.
26. Tyagi, P., Tyagi, V., Yoshimura, N., Chancellor, M., Yamaguchi, O. βετα;3-adrenoceptor agonists for the treatment of overactive bladder. Drugs Fut 2009, 34(8): 635-40.
27. Takasu, T., Ukai, M., Sato, S. et al. Effect of (R)-[2-(2- aminothiazol-4-yl)-4′-2-[(2-hydroxy-2-phenylethyl)- amino]ethyl] acetanilide (YM178), a novel selective beta3- adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007, 321(2): 642-7. (Pubitemid 46624504)
28. Noguchi, Y., Someya, A., Ukai, M., Nakata, M., Ohtake, A., Suzuki, M., Sasamata, M. Effects of mirabegron (YM178) on non-micturition contractions in the bladder of conscious rats with bladder outlet obstruction (BOO). J Urol [Annu Meet Am Urol Assoc (AUA) (April 25-30, Chicago) 2009] 2009, 181(4, Suppl.): Abst 25.
29. Gillespie, J., Guilloteau, V., Korstanje, C., Lluel, P., Palea, S. Differences in the actions of the M3-antagonist tolterodine and the beta 3 adrenoceptor agonist mirabegron on nonvoiding activity in rats with partial outflow obstruction. Neurourol Urodyn [Int Continence Soc/Int Urogynecol Assoc (ICS/IUGA) Joint Meet (Aug 23-27, Toronto) 2010] 2010, 29(6): Abst 202.
30. Someya, A., Ukai, M., Yanai, H. et al. Mirabegron (YM178), a novel beta3-adrenoceptor (AR) agonist, increased functional bladder capacity and decreased micturition frequency in conscious water-loaded cynomolgus monkeys. Eur Urol Suppl [25th Congr Eur Assoc Urol (April 16-20, Barcelona) 2010] 2010, 9(2): Abst 266.
31. Aizawa, N., Homma, Y., Igawa, Y. Effects of mirabegron (YM178), a novel beta3-adrenoceptor agonist, on the primary bladder afferent activity of the rat. Neurourol Urodyn [41st Annu Meet Int Continence Soc (Aug 29-Sept 2, Glasgow) 2011] 2011, 30(6): Abst 154.
32. Veltkamp, S., Gelderen, M., Schaddelee, M., Krauwinkel, W., Koning, P. Clinical study into the pharmacokinetic, pharmacodynamic and safety interaction of the novel beta3-adrenoceptor agonist mirabegron and metformin in healthy subjects. Basic Clin Pharmacol Toxicol [9th Congr Eur Assoc Clin Pharmacol Ther (EACPT) (July 12-15, Edinburgh) 2009] 2009, 105(Suppl. 1): Abst WP107.
33. van Gelderen, E.M., Li, Q., Meijer, J., Schaddelee, M.P., Takusagawa, S., Sugawara, T., de Koning, P. An exploratory comparison of the single dose pharmacokinetics of the beta3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 18-21, Washington, D.C.) 2009] 2009, 85(Suppl. 1): Abst PIII-65.
34. Zanger, U.M., Raimundo, S., Eichelbaum, M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, and biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004, 369(1): 23-37. (Pubitemid 38161221)
35. Krauwinkel, W.J., van Gelderen, E.M., Groen, M.J., Schaddelee, M., de Koning, P. An open-label, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects. Clin Pharmacol Ther [111st Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 17-20, Atlanta) 2010] 2010, 87(Suppl. 1): Abst PIII- 65.
36. Sawamoto, T., Lee, J., Alak, A. et al. Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects. Clin Pharmacol Ther [112th Annu Meet Am Soc Clin Pharm Ther (March 2-5, Dallas) 2011] 2011, 89(Suppl. 1): Abst PI- 43.
37. Sawamoto, T., Lee, J., Cao, Y. et al. Phase I, open-label, drug interaction study to evaluate the effect of repeat doses of rifampin on the single-dose pharmacokinetics of mirabegron (YM178) in healthy adult subjects. Clin Pharmacol Ther [112th Annu Meet Am Soc Clin Pharm Ther (March 2-5, Dallas) 2011] 2011, 89(Suppl. 1): Abst PI-44.
38. Chapple, C.R., Yamaguchi, O., Ridder, A. et al. Clinical proof of concept study (BLOSSOM) shows novel beta3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl [23rd Congr Eur Assoc Urol (March 26-29, Milan) 2008] 2008, 7(3): Abst 674.
39. Chapple, C., Wyndaele, J.J., Van Kerrebroeck, P. et al. Doseranging study of once-daily mirabegron (YM178), a novel selective beta3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol Suppl [25th Congr Eur Assoc Urol (April 16-20, Barcelona) 2010] 2010, 9(2): Abst 774.
40. Nitti, V., Herschorn, S., Auerbach, S., Ayers, M., Lee, M., Martin, N. The selective beta3-adrenoreceptor agonist mirabegron is effective and well tolerated in patients with overactive bladder syndrome. Annu Meet Am Urol Assoc (AUA) (May 14-19, Washington, D.C.) 2011, Abst 1958.
41. Nitti, V., Herschorn, S., Auerbach, S., Martin, N., Blauwet, M.B., Marshall, T. Mirabegron improves patient-reported outcomes in patients with overactive bladder syndrome - Results from a North-American study. Annu Meet Am Urol Assoc (AUA) (May 14-19, Washington, D.C.) 2011, Abst 1959.
42. Nitti, V., Herschorn, S., Auerbach, S., Ayers, M., Lee, M., Martin, N. The efficacy and safety of mirabegron in patients with overactive bladder syndrome - Results from a North- American Phase III trial. 26th Congr Eur Assoc Urol (March 18-22, Vienna) 2011, Abst 885.
43. Nitti, V., Herschorn, S., Lee, M., Martin, N. Efficacy and tolerability of once-daily mirabegron, a potent and selective beta3-adrenoceptor agonist, in patients with overactive bladder. Results from a North American phase III trial. Neurourol Urodyn [41st Annu Meet Int Continence Soc (Aug 29-Sept 2, Glasgow) 2011] 2011, 30(6): Abst 92.
44. Khullar, V., Cambronero, J., Stroeberg, P., Angulo, J., Boerrigter, P., Blauwet, M.B., Wooning, M. The efficacy and tolerability of mirabegron in patients with overactive bladder - Results from a European-Australian phase III trial. 26th Congr Eur Assoc Urol (March 18-22, Vienna) 2011, Abst 886.
45. Khullar, V., Cambronero, J., Stroeberg, P., Angulo, J., Boerrigter, P., Wooning, M. The efficacy and tolerability of mirabegron, a potent and selective beta3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder: Results from a European- Australian phase III trial. Neurourol Urodyn [41st Annu Meet Int Continence Soc (Aug 29-Sept 2, Glasgow) 2011] 2011, 30(6): Abst 328.